NIDDK, Phoenix
Phoenix, Arizona, 85014, United States
NCT Number: NCT00339313
This protocol is for study of the effect of inhibition of parasympathetic outflow on insulin secretion and glucose metabolism. Insulin secretion will be measured during infusions of escalating doses of atropine. Other clinical parameters of parasympathetic inhibition by atropine will also be assessed.
Looking for future studies?
Notify Me7 year–10 year
All sexes
Observational
Phoenix, Arizona, 85014, United States
Children of mothers who had diabetes during pregnancy are at an increased risk of diabetes and obesity in later life, effects partly mediated by the early environment experienced by the offspring of diabetic mothers in utero. In this protocol, we address why intra-uterine exposure to maternal diabetes might lead to later childhood obesity. Previous studies of children of diabetic mothers have not detected any alteration in energy expenditure, either as resting metabolic rate or physical activity. We will now examine whether they are at an increased risk of obesity due to differences in food intake. We will assess composition of the diet, patterns of eating, taste preference and physiological responses to a mixed meal. No previous work in human subjects has addressed these issues.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Group 1: Offspring of mothers with diabetes during pregnancy.
Maternal diagnosis of type 2 diabetes (by WHO criteria after a 75g OGTT or on clinical grounds with at least one random plasma glucose greater than 200mg/dl) before or during the index pregnancy.
Group 2: Offspring of mothers with diabetes diagnosed following pregnancy.
Maternal diagnosis of type 2 diabetes (by WHO criteria after a 75g OGTT or on clinical grounds with at least one random plasma glucose greater than 200 mg/dl) after the index pregnancy.
It is important to also ensure that these mothers did not have any major disturbance in glucose tolerance during the index pregnancy and a record of normal glucose tolerance after the index pregnancy; therefore they will only be included if there are also:
Adequate records of glucose testing during the index pregnancy and these records are not in keeping with a diagnosis of gestational diabetes (by either WHO criteria if a 75g oral glucose tolerance test has been carried out).
At least one non-diabetic OGTT after the index pregnancy.
Exclusion criteria
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT01809288
Behavior, Body Weight
Bethesda, Maryland, United States
View Trial DetailsNCT06268990
Body Weight, Diabetes
Graz, Austria
View Trial Details